Epigenetic code during mycobacterial infections : therapeutic implications for tuberculosis
Epigenetics involves changing the gene function without any change in the sequence of the genes. In the case of tuberculosis (TB) infections, the bacilli, Mycobacterium tuberculosis( M.tb), uses epigenetics as a tool to protect itself from the host immune system. TB is a deadly disease‐causing maximum death per year due to a single infectious agent. In the case of TB, there is an urgent need for novel host‐directed therapies which can effectively target the survival and long‐term persistence of the bacteria without developing drug resistance in the bacterial strains while also reducing the duration and toxicity associated with the mainstream anti‐TB drugs. Recent studies have suggested that TB infection has a significant effect on the host epigenome thereby manipulating the host immune response in the favor of the pathogen. M.tb alters the activation status of key genes involved in the immune response against TB to promote its survival and subvert the antibacterial strategies of the host. These changes are reversible and can be exploited to design very efficient host‐directed therapies to fight against TB. This review has been written with the purpose of discussing the role of epigenetic changes in TB pathogenesis and the therapeutic approaches involving epigenetics, which can be utilized for targeting the pathogen..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:289 |
|---|---|
| Enthalten in: |
The FEBS Journal - 289(2022), 14, Seite 4172-4191 |
| Beteiligte Personen: |
Fatima, Samreen [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
Copyright © 2022 Federation of European Biochemical Societies |
|---|
| Umfang: |
4191 |
|---|
| doi: |
10.1111/febs.16170 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY005691265 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY005691265 | ||
| 003 | DE-627 | ||
| 005 | 20230307152700.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230215s2022 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/febs.16170 |2 doi | |
| 028 | 5 | 2 | |a FEBS_FEBS16170.xml |
| 035 | |a (DE-627)WLY005691265 | ||
| 035 | |a (WILEY)FEBS16170 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 540 |a 570 |a 610 |q ASE |
| 084 | |a 35.70 |2 bkl | ||
| 100 | 1 | |a Fatima, Samreen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Epigenetic code during mycobacterial infections |b therapeutic implications for tuberculosis |
| 264 | 1 | |c 2022 | |
| 300 | |a 4191 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Copyright © 2022 Federation of European Biochemical Societies | ||
| 520 | |a Epigenetics involves changing the gene function without any change in the sequence of the genes. In the case of tuberculosis (TB) infections, the bacilli, Mycobacterium tuberculosis( M.tb), uses epigenetics as a tool to protect itself from the host immune system. TB is a deadly disease‐causing maximum death per year due to a single infectious agent. In the case of TB, there is an urgent need for novel host‐directed therapies which can effectively target the survival and long‐term persistence of the bacteria without developing drug resistance in the bacterial strains while also reducing the duration and toxicity associated with the mainstream anti‐TB drugs. Recent studies have suggested that TB infection has a significant effect on the host epigenome thereby manipulating the host immune response in the favor of the pathogen. M.tb alters the activation status of key genes involved in the immune response against TB to promote its survival and subvert the antibacterial strategies of the host. These changes are reversible and can be exploited to design very efficient host‐directed therapies to fight against TB. This review has been written with the purpose of discussing the role of epigenetic changes in TB pathogenesis and the therapeutic approaches involving epigenetics, which can be utilized for targeting the pathogen. | ||
| 700 | 1 | |a Kumari, Anjna |4 aut | |
| 700 | 1 | |a Agarwal, Meetu |4 aut | |
| 700 | 1 | |a Pahuja, Isha |4 aut | |
| 700 | 1 | |a Yadav, Vinod |4 aut | |
| 700 | 1 | |a Dwivedi, Ved Prakash |4 aut | |
| 700 | 1 | |a Bhaskar, Ashima |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The FEBS Journal |g 289(2022), 14, Seite 4172-4191 |w (DE-627)WLY005674662 |x 17424658 |7 nnns |
| 773 | 1 | 8 | |g volume:289 |g year:2022 |g number:14 |g pages:4172-4191 |g extent:4191 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 35.70 |q ASE |
| 951 | |a AR | ||
| 952 | |d 289 |j 2022 |e 14 |h 4172-4191 |g 4191 | ||